CYTOSORBENTS CORPORATION (CTSO) Gross margin 2016–2025
CYTOSORBENTS CORPORATION (CTSO) gross margin by fiscal year — reported gross profit divided by reported revenue.
71.5%FY2025 · since FY2016: 58.5% → 71.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 71.5% | +1.6 pp |
| FY2024 | 69.9% | -0.7 pp |
| FY2023 | 70.6% | +10.9 pp |
| FY2022 | 59.8% | -14.6 pp |
| FY2021 | 74.4% | +1.4 pp |
| FY2020 | 73.0% | +2.6 pp |
| FY2019 | 70.5% | +3.8 pp |
| FY2018 | 66.7% | +3.1 pp |
| FY2017 | 63.6% | +5.1 pp |
| FY2016 | 58.5% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTSO financial trends
CTSO RevenueCTSO Net incomeCTSO Net marginCTSO Gross profitCTSO Operating incomeCTSO Operating marginCTSO Operating cash flowCTSO Free cash flowCTSO Capital expendituresCTSO Return on equityCTSO Stock buybacksCTSO Dividends paidCTSO Total assetsCTSO Total liabilitiesCTSO Shareholders’ equityCTSO overview →